Effects of testosterone gel treatment in hypogonadal men with liver cirrhosis

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 12, 2011, Pages 845-854

  Yurci, Alper ^a   Yucesoy, Mehmet ^a   Unluhizarci, Kursad ^a   Torun, Edip ^a   Gursoy, Sebnem ^a   Baskol, Mevlut ^a   Guven, Kadri ^a   Ozbakir, Omer ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN; CREATININE; FOLLITROPIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; SERUM ALBUMIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; BLEEDING; BODY COMPOSITION; BONE DENSITY; BRAIN DISEASE; BREAST; BREAST DISEASE; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; EDEMA; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; GYNECOMASTIA; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOGONADISM; LIVER CIRRHOSIS; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MALIGNANT NEOPLASTIC DISEASE; MUSCLE STRENGTH; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROTHROMBIN TIME; SCAPULA; SKIN IRRITATION; TENDERNESS OF NIPPLE; TESTOSTERONE BLOOD LEVEL; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL; CLINICAL TRIAL; GEL; MIDDLE AGED; PROSPECTIVE STUDY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; GELS; HUMANS; HYPOGONADISM; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TESTOSTERONE;

EID: 84859516004     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.09.005     Document Type: Article

References (44)

1. Kaymakoĝlu S., ökten A., çakaloĝlu Y., Boztaş G., Beşi{dotless}şi{dotless}k F., Taşçi{dotless}oĝlu C., et al. Hypogonadism is not related to the etiology of liver cirrhosis. J Gastroenterol 1995, 30(6):745-750.
2. Baker H.W.G., Burger H.G., De Kretser D.M., Dulmanis A., Hudson B., O'Connor S., et al. A study of the endocrine manifestations of hepatic cirrhosis. Q J Med 1976, 45:145-178.
3. Wang Y.J., Wu J.C., Lee S.D., Lee Y.T., Tsai K.J.L. Gonadal dysfunction and changes in sex hormones in postnecrotic cirrhotic men: a matched study with alcoholic cirrhotic men. Hepatogastroenterology 1991, 38:531-534.
4. Wang Y.J., Lee S.D., Lin H.C., Hsia H.C., Lee F.Y., Tsai Y.T., et al. Changes of sex hormone levels in patients with hepatitis B related postnecrotic cirrhosis: relationship to the severity of portal hypertension. J Hepatol 1993, 18:101-105.
5. Gordon G.G., Olivo J., Fereidoon R., Southern A.L. Conversion of androgens to estrogen in cirrhosis of the liver. J Clin Endocrinol Metab 1975, 40:1018-1026.
6. Kley H.K., Niederau C., Stremmel W., Lax R., Strohmeyer G., Kruskemper H.L. Conversion of androgens to estrogens in idiopathic hemochromatosis: comparison with alcoholic liver cirrhosis. J Clin Endocrinol Metab 1985, 61:1-6.
7. Moradian A.D., Shamma M., Salti I., Cortas N. Hypophyseal-gonadal dysfunction in men with non-alcoholic liver cirrhosis. Andrologia 1985, 17:72-79.
8. Zaitoun A.M., Apelqvist G., Wikell C., Al-Mardini H., Bengtsson F., Record C.O. Quantitative studies of testicular atrophy following portocaval shunt in rats. Hepatology 1998, 28:1461-1466.
9. Mowat N.A.G., Edwards C.R.W., Fisher R., McNeilly A.S., Green J.R.B., Dawson A.M. Hypothalamic-pituitary-gonadal function in men with cirrhosis of the liver. Gut 1976, 17:345-350.
10. Bennett H.S., Baggenstoss A.H., Butt HR The testis, breast and prostate of men who die of cirrhosis of the liver. Am J Clin Pathol 1950, 20:814-817.
11. Cavanough J., Niewoehner C.B., Nuttall F.Q. Gynecomastia and cirrhosis of the liver. Arch Intern Med 1990, 150:563-565.
12. Rouillard S., Lane N.E. Hepatic Osteodystrophy. Hepatology 2001, 33:301-307.
13. Chappard D., Plantard P., Fraisse H., Palle S., Alexandre C., Riffat G. Bone changes in alcoholic cirrhosis of the liver. Path Res Pract 1989, 184:480-485.
14. Gallego-Rojo F.J., Gonzalez-Calvin J.L., Munoz-Torres M., Mundi J.L., Fernandez-Perez R., Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998, 28:695-699.
15. Hay J.E. Bone disease in cholestatic liver disease. Gastroenterology 1995, 108:276-283.
16. Mitchison H.C., Malcolm A.J., Bassendine M.F., James O.F.W. Metabolic bone disease in primary biliary cirrhosis at presentation. Gastroenterology 1988, 94:463-470.
17. Wang C., Swerdloff R.S. Androgen replacement therapy. Ann Med 1997, 29:365-370.
18. Wang C., Swerdloff R.S., Iranmanesh A., Dobs A., Snyder P.J., Cunningham G., et al. Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000, 85:2839-2853.
19. Wang C., Cunningham G., Dobs A., Iranmanesh A., Matsumoto A.M., Snyder P.J., et al. Long-term testosterone gel (Androgel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004, 89:2085-2098.
20. Neff G.W., O'Brien C.B., Montalbano M., Meyer D., DeManno A., Muslu H., et al. Beneficial effects of topical testosterone replacement in patients with end-stage liver disease. Dig Dis Sci 2004, 49:1186-1189.
21. Neff G.W., O'Brien C.B., Shire N.J., DeManno A., Kahn S., Rideman E., et al. Topical testosterone treatment for chronic allograft failure in liver transplant recipients with recurrent hepatitis C virus. Transplantation Proceedings 2004, 36:3071-3074.
22. Hengge U HIV and testosterone therapy [comment]. Lancet Infect Dis 2003, 3:187-188.
23. Rabkin J.G., Wagner G.J., Rabkin R. A double-blind, placebo controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000, 57:141-147.
24. Vermeulen A., Verdonck L., Kaufman J.M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84:3666-3672.
25. Kley H.K., Herrmann J., Morgner K.D., Krüskemper H.L. Effects of testosterone enanthate on plasma concentrations of thyroxine, cortisol, testosterone and hormone binding proteins in patients with hypogonadism. Horm Metab Res 1973, 5:271-275.
26. Bahnsen M., Gluud C., Johnsen S.G., Bennett P., Svenstrup S., Micic S., et al. Pituitary-testicular function in patients with alcoholic cirrhosis of the liver. Eur J Clin Invest 1981, 11:473-479.
27. Fritz K.S., McKean A.J.S., Nelson J.C., Wilcox R.B. Analog-based free testosterone test results linked to total testosterone concentrations, not free testosterone concentrations. Clin Chem 2008, 54:512-516.
28. Swerdloff R.S., Wang C. Free testosterone measurement by the analog displacement direct assay: Old concerns and new evidence. Clin Chem 2008, 54:458-460.
29. Rosner W. An extraordinarily inaccurate assay for free testosterone is still with us. J Clin Endocrinol Metab 2001, 86:2903.
30. Yamamoto K., Koh E., Matsui F., Sugimoto K., Sin H.S., Maeda Y., et al. Measurement specific bioavailable testosterone using concanavalin A precipitation: comparison of calculated and assayed bioavailable testosterone. Int J Urol 2009, 16:894-901.
31. Deóchaud H., Denuziere A., Rinaldi S., Bocquet J., Lejeune H., Pugeat M. Age-associated discrepancy between measured and calculated bioavailable testosterone in men. Clin Chem 2007, 53:723-728.
32. Lakshman K.M., Basaria S. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging 2009, 4:397-412.
33. de Ronde W., Vogel S., Bui H.N., Heijboer A.C. Reduction in 24-hour plasma testosterone levels in subjects who showed 15 or 30minutes after application of testosterone gel. Pharmacotherapy 2011, 31:248-252.
34. Gluud C., Bennett P., Svenstrup B., Micic S. Effect of testosterone treatment on serum concentrations of sex steroids gonadotrophins and prolactin in alcoholic cirrhotic men. Aliment Pharmacol Ther 1988, 2:119-128. Copenhagen study group for liver disease.
35. The Copenhagen study group for liver diseases Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. Hepatology 1986, 6:807-813.
36. Kley H.K., Stremmel W., Kley J.B., Schlaghecke R. Testosterone treatment of men with idiopathic hemochromatosis. Clin İnvestig 1992, 70:566-572.
37. Katznelson L., Finkelstein J.S., Schoenfeld D.A., Rosenthal D.I., Anderson E.J., Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996, 81:4358-4365.
38. Diamond T., Stiel D., Posen S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J Bone Miner Res 1991, 6:39-43.
39. Collier J.D., Ninkovic M., Compston J.E. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002, 50(suppl I):i1-i9.
40. Isidori A.M., Giannetta E., Greco E.A., Gianfrilli D., Bonifacio V., Isidori A., et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men. A meta-analysis. Clin Endocrinol 2005, 63:280-293.
41. Abate N., Garg A., Peshock R.M., Stray-Gunderson J., Grundy SM Relationships of generalized and regional adiposity to insulin sensitivity. J Clin Invest 1995, 96:88-98.
42. Marin P., Holmang S., Jonsson L., Sjostrom L., Kvist H., Holm G., et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992, 16:991-997.
43. Nindl B.C., Kraemer W.J., Gotshalk L.A., Marx J.O., Volek J.S., Bush F.A., et al. Testosterone responses after resistance in women: influence of regional fat distribution. Int J Sport Nutr Exerc Metab 2001, 11:451-465.
44. Snyder P.J., Peachey H., Berlin J.A., Rader D., Usher D., Loh L., et al. Effects of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am J Med 2001, 111:255-260.